The mucopolysaccharidoses are a group of lysosomal storage diseases caused by deficiency of an enzyme required for the normal degradation of glycosaminoglycans. Patients with mucopolysaccharidosis typically have widespread lysosomal storage, skeletal and central nervous system disease, and hepatosplenomegaly. Some patients with mucopolysaccharidosis may benefit from enzyme replacement therapy or bone marrow transplantation. Animal models of mucopolysaccharidosis have proven valuable for the evaluation of the effectiveness of potential treatments for patients with lysosomal storage disease. A murine model of MPS VII (Sly syndrome) has proven particularly useful because of its well-defined genetics and its well-characterized clinical, pathologic, and biochemical alterations, which resemble those seen in patients with mucopolysaccharidosis. Correction of these alterations forms the basis for evaluation of the effectiveness of novel treatments. A wide range of therapies have been tested using this model, including enzyme replacement therapy, bone marrow, stem cell, and neural progenitor cell transplantation, and a variety of viral-mediated gene therapies. The inferences drawn from these therapeutic studies using the murine MPS VII model are likely generalizable to other lysosomal storage diseases.
MeiklePJ, HopwoodJJ, ClagueAE, CareyWF. Prevalence of lysosomal storage disorders. JAMA1999;281;249–254.
2.
NeufeldEF, MuenzerJ.The mucopolysaccharidosis. In: ScriverCR, BeaudetAL, SlyWS, , eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001:3421–3452.
3.
SlyWS, QuintonBA, McAlisterWH, RimoinDL. β-glucuronidase deficiency: report of clinical radiologic and biochemical features of a new mucopolysaccharidosis. J Pediatr1973;82:249–257.
4.
VoglerCA, LevyB, KyleJW, SlyWS, WilliamsonJ, WhiteMP. Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with β-glucuronidase deficiency. Mod Pathol1994;7:132–137.
5.
KrivitW, PetersC, ShapiroEG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucoaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol1999;12:167–176.
6.
KakkisED, MuenzerJ, TillerGE, Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med2001;344:182–188.
7.
HaskinsME, AguirreGD, JezykPF, SchuchmanEH, DesnickRJ, PattersonDF. Animal model of human disease: mucopolysaccharidosis type VII (Sly syndrome). Beta-glucuronidase-deficient mucopolysaccharidosis in the dog. Am J Pathol1991;138:1553–1555.
8.
GitzelmannR, BosshardNU, Superti-FurgaA, Feline mucopolysaccharidosis VII due to β-glucuronidase deficiency. Vet Pathol1994;31:435–443.
9.
BirkenmeierEH, DavissonMT, BeamerWG, Murine mucopolysaccharidosis type VII: characterization of a mouse with β-glucuronidase deficiency. J Clin Invest1989; 83:1258–1266.
10.
CasalML, WolfeJH. Variant clinical course of mucopolysaccharidosis type VII in two groups of mice carrying the same mutation. Lab Invest1998;78:1575–1581.
11.
GwynnB, LuedersK, SandsMS, BirkenmeierEH. Intra-cisternal A-particle element transposition into the murine β-glucuronidase deficiency in the C3H mouse. Mol Cell Biol1998;18:6474–6481.
12.
FyfeJC, KurzhalsRL, LassalineME, Molecular basis of feline β-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Genomics1999;58:121–128.
13.
VoglerC, LevyB, GalvinN, A novel model of murine mucopolysaccharidosis type VII due to an intracisternal A particle element transposition into the β-glucuronidase gene: clinical and pathologic findings. Pediatr Res2001; 49:342–348.
14.
VoglerC, BirkenmeierEH, SlyWS, A murine model of mucopolysaccharidosis VII: gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol1990;136:207–217.
15.
SandsMS, BirkenmeierEH. A single-base-pair deletion in the β-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci USA1993;90:6567–6571.
16.
CasalML, WolfeJH. Mucopolysaccharidosis type VII in the developing mouse fetus. Pediatr Res2000;47:750–756.
17.
KyleJW, BirkenmeierEH, GwynnB, Correction of murine mucopolysaccharidosis VII by a human β-glucuronidase transgene. Proc Natl Acad Sci USA1990;87:3914–3918.
18.
DalyTM, LorenzRG, SandsMS. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr Res2000;47:757–762.
19.
SlyWS, VoglerC, GrubbJH, Active site mutant transgene confers tolerance to human β-glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci USA2001;98:2205–2210.
20.
SandsMS, ErwayLC, VoglerC, SlyWS, BirkenmeierEH. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood1995;86:2033–2040.
21.
O'ConnorLH, ErwayLC, VoglerCA, Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Invest1998;101:1394–1400.
22.
SoperBW, PungAW, VoglerCA, GrubbJH, SlyWS, BarkerJE. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Pediatr Res1999;45:180–186.
23.
KintJA, DacremontG, CartonD, OryeE, HooftC.Mucopolysaccharidosis: secondarily induced abnormal distribution of lysosomal isoenzymes. Science1973;181:352.
24.
FrisellaWA, O'ConnorLH, VoglerCA, Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther2001;3:351–358.
25.
GalvinNJ, LevyB, VoglerC.Brain morphology in murine mucopolysaccharidosis (MPS) type VII [abstract]. Mol Biol Cell1994;55:360A.
26.
LevyB, GalvinN, VoglerC, BirkenmeierEH, SlyWS. Neuropathology of murine mucopolysaccharidosis type VII. Acta Neuropathol1996;92:562–568.
27.
LazarusHS, SlyWS, KyleJW, HagemanGS. Photoreceptor degeneration and altered distribution of interphotoreceptor matrix proteoglycans in the mucopolysaccharidosis VII mouse. Exp Eye Res1993;56:531–541.
28.
OhlemillerKK, VoglerCA, RobertsM, GalvinN, SandsMS. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp Eye Res2000;71:469–481.
29.
BerryCL, VoglerC, GalvinNJ, BirkenmeierEH, SlyWS. Pathology of the ear in murine mucopolysaccharidosis type VII: morphologic correlates of hearing loss. Lab Invest1994;71:438–445.
30.
Gritli-LindeA, LindeA, GoldbergM.Morphological alterations in dental and periodontal tissues in murine mucopolysaccharidosis type VII. Calcif Tissue Int1995;57:178–184.
31.
DialS, NorrdinR.Morphometric changes in the growth plate of mucopolysaccharidosis VII (MPS VII) affected mice [abstract]. Vet Pathol1992;29:435.
32.
SoperBW, LessardMD, VoglerCA, Nonablative neonatal marrow transplantation attenuates functional and physical defects of β-glucuronidase deficiency. Blood2001;97:1498–1504.
33.
SandsMS, BarkerJE, VoglerC, Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest1993;68:676–686.
34.
SoperBW, DuffyTM, VoglerCA, BarkerJE. A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. Exp Hematol1999;27:1691–1704.
35.
BirkenmeierEH, BarkerJE, VoglerCA, Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood1991;78:3081–3092.
36.
PoorthuisBJHM, RommeAE, WillemsenR, WagemakerG.Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Pediatr Res1994;36:187–193.
37.
BastedoL, SandsMS, LambertDT, PisaMA, BirkenmeierE, ChangPL. Behavioral consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII. J Clin Invest1994;94:1180–1186.
38.
FreemanBJ, RobertsMS, VoglerCA, NicholesA, HoflingAA, SandsMS. Behavior and therapeutic efficacy of β-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood1999;94:2142–2150.
39.
OhashiT, YokooT, LizukaS, KobayashiH, SlyWS, EtoY.Reduction of lysosomal storage in murine mucopolysaccharidosis type VII by transplantation of normal and genetically modified macrophages. Blood2000;95:3631–3633.
40.
CasalML, WolfeJH. In utero transplantation of fetal liver cells in the mucopolysaccharidosis type VII mouse results in low-level chimerism, but overexpression of β-glucuronidase can delay onset of clinical signs. Blood2001;97:1625–1634.
41.
SnyderEY, TaylorRM, WolfeJH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature1995;374:367–370.
42.
GrubbJH, KyleJW, CodyLB, SlyWS. Large scale purification of phosphorylated recombinant human β-glucuron-idase from overexpressing mouse L cells. FASEB J1993; 7A1255.
43.
VoglerC, SandsM, HigginsA, Enzyme replacement with recombinant β-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res1993;34:837–840.
44.
SandsMS, VoglerC, KyleJW, Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest1994;93:2324–2331.
45.
VoglerC, LevyB, GalvinNJ, Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to β-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res1999;45:838–844.
46.
VoglerC, SandsMS, LevyB, GalvinN, BirkenmeierEH, SlyWS. Enzyme replacement with recombinant β-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res1996;39:1050–1054.
47.
SandsMS, VoglerC, TorreyA, Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest1997;99:1596–1605.
48.
RossCJD, BastedoL, MaierSA, SandsMS, ChangPL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther2000;11:2117–2127.
49.
RossCJD, RalphM, ChangPL. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol2000;166:276–286.
SandsMS, WolfeJH, BirkenmeierEH, Gene therapy for murine mucopolysaccharidosis type VII. Neuromuscul Disord1997;7:352–360.
52.
VoglerC, SandsMS, GalvinN, Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J Inherit Metab Dis1998;21:575–586.
53.
WolfeJH, SandsMS, BarkerJE, Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature1992;360:749–753.
54.
MoullierP, BohlD, HeardJM, DanosO.Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat Genet1993;4:154–159.
55.
MarechalV, NaffakhN, DanosO, HeardJM. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. Blood1993;82:1358–1365.
56.
GaoC, SandsMS, HaskinsME, PonderKP. Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther2000;2:233–244.
57.
TaylorRM, WolfeJH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of β-glucuronidase. Nat Med1997;3:771–774.
58.
WolfeJH, DeshmaneSL, FraserNW. Herpesvirus vector gene transfer and expression of β-glucuronidase in the central nervous system of MPS VII mice. Nat Genet1992; 1:379–384.
59.
ZhuJ, KangW, WolfeJH, FraserNW. Significantly increased expression of β-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector. Mol Ther2000; 2:82–94.
60.
BoschA, PerretE, DesmarisN, TronoD, HeardJM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther2000;11:1139–1150.
61.
KosugaM, TakahashiS, SasakiK, Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-41g coexpression. Mol Ther2000;1:406–413.
62.
OhashiT, WatabeK, UeharaK, SlyWS, VoglerC, EtoY.Adenovirus-mediated gene transfer and expression of human β-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci USA1997;94:1287–1292.
63.
LiT, DavidsonBL. Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc Natl Acad Sci USA1995;92:7700–7704.
64.
KosugaM, TakahashiS, SasakiK, Phenotype correction in murine mucopolysaccharidosis type VII by transplantation of human amniotic epithelial cells after adenovirus-mediated gene transfer. Cell Transplant2000; 9:687–692.
65.
KosugaM, SasakiK, TanabeA, Engraftment of genetically engineered amniotic epithelial cells corrects lysosomal storage in multiple areas of the brain in mucopolysaccharidosis type VII mice. Mol Ther2001;3:139–148.
66.
GhodsiA, SteinC, DerksenT, YangG, AndersonRD, DavidsonBL. Extensive β-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum Gene Ther1998;9:2331–2340.
67.
SteinCS, GhodsiA, DerksenT, DavidsonBL. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol1999;73:3424–3429.
68.
GhodsiA, SteinC, DerksenT, MartinsI, AndersonRD, DavidsonBL. Systemic hyperosmolality improves β-glu-curonidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol1999;160:109–116.
69.
DalyTM, OkuyamaT, VoglerC, HaskinsME, MuzyczkaN, SandsMS. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged β-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther1999;10:85–94.
70.
DalyTM, VoglerC, LevyB, HaskinsME, SandsMS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA1999;96:2296–2300.
71.
DalyTM, OhlemillerKK, RobertsMS, VoglerCA, and SandsMS. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther2001 (in press).
72.
DonsanteA, VoglerCA, MuzyczkaN, Observed incident of tumorigenesis in long-term rodent studies of rAAV vectors: are recombinant AAV-based vectors inherently safe?Gene Ther2001 (in press).
73.
SkorupaAF, FisherKJ, WilsonJM, ParenteMK, WolfeJH. Sustained production of β-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol1999;160:17–27.
74.
BoschA, PerretE, DesmarisN, HeardJM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther2000;1:63–70.
75.
ElligerSS, ElligerCA, AguilarCP, RajuNR, WatsonGL. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther1999;6:1175–1178.
76.
SferraTJ, QuG, McNeelyD, Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther2000;11: 507–519.
